Ofatumumab — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

3 Recruiting

4 Completed trials

6 Sponsors

24 Countries

Phase III

Phase II

Phase IV

Phase III: 5 Phase II: 4 Phase IV: 1

Indications tested

Multiple sclerosis relapse 4 Multiple sclerosis 3 Relapsing-remitting multiple sclerosis 3 Progressive multiple sclerosis 2 Primary progressive multiple sclerosis 1 Nervous system disorder 1 Secondary progressive multiple sclerosis 1

Sponsors using this IMP

Novartis Pharma AG 5 Antwerp University Hospital 1 Centre Hospitalier Universitaire De Nantes 1 Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S 1 Kyverna Therapeutics Inc. 1 Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy 1

All trials

10 total

PRObiotic Therapy Examining Combinatorial Therapeutics in Multiple Sclerosis - phase II, multicenter, randomised, open-label clinical trial. Not authorised

2025-520955-10-00 Phase II 1 country Wojskowy Instytut Medyczny Panstwowy Instytut Badawczy
A Study of Anti-CD19 CAR T-cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis Pending

2024-511168-10-00 Phase II 4 countries Kyverna Therapeutics Inc.
DESIRE MS: A prospective randomized non-inferiority trial comparing anti-CD20 maintenance versus De-Escalation Strategy In Relapsing-Remitti… Pending

2024-513292-40-00 Phase III 1 country Centre Hospitalier Universitaire De Montpellier
Concentration of ofatumumab in the breast milk of lactating women with relapsing forms of multiple sclerosis Recruiting

2023-505283-11-00 Phase IV 4 countries Novartis Pharma AG
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis Recruiting

2024-511686-11-00 Phase III 13 countries Novartis Pharma AG
No Evidence Of Disease Activity After Autologous Haematopoietic Stem Cell Transplantation In Aggressive Multiple Sclerosis Recruiting

2024-515470-26-00 Phase II 1 country Fondazione Italiana Sclerosi Multipla Ente Del Terzo Settore/et S
Metformin add-on clinical study in multiple sclerosis to evaluate brain remyelination and neurodegeneration: a phase IIb triple-blind placeb… Ended

2023-503190-38-00 Phase II 1 country Antwerp University Hospital
An open-label extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with RMS Ended

2023-507906-15-00 Phase III 21 countries Novartis Pharma AG
Study of efficacy and tolerability of ofatumumab vs. First Line disease modifying treatment (DMT) - physician’s choice in the treatment of n… Ended

2023-507431-37-00 Phase III 4 countries Novartis Pharma AG
An open-label study evaluating ofatumumab treatment effectiveness and PROs in subjects with RMS transitioning from fumarate-based RMS approv… Ended

2023-507493-41-00 Phase III 8 countries Novartis Pharma AG

Showing 1–10 of 10 trials

← All drugs A–Z